- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04125628
Exercise on Multiple Sclerosis Patients
October 11, 2019 updated by: Petros Dinas
Effects of Head and Neck Cooling on Functional Ability and Fatigue of Multiple Sclerosis
Multiple sclerosis (MS) patients are characterized by thermoregulatory failure, known as Uthoff's phenomenon.
Precisely, 60-80% of the MS patients present adverse clinical symptoms when their body temperature is increased.
Thus, the development of treatment strategies to overcome the thermoregulatory problem in these patients is crucial.
Given that cooling has been proposed as an effective method, the aim of this study was to examine whether the application of head cooling therapy during an exercise training session is capable to prevent the core temperature increase and to improve the patient's functional ability and quality of life.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Multiple Sclerosis (MS) mostly affects young individuals aged between 20 to 40 years and is the leading cause of morbidity and disability in young.
Most of the MS patients experience motor symptoms such as ataxia, tremor, dizziness, limb weakness and vertigo that induce gait difficulty.
More precisely, it has been reported that in around 85% of patients diagnosed with MS the gait difficulties are the main problem, which increases the risk for falls.
Except for the motor difficulties, MS patients experience multiple physical, cognitive and neurological symptoms that reduce their quality of life.
Also, fatigue is another frequent symptom, which is considered among the most disabling symptoms.
MS patients 10 years after the onset of the disease become unable to perform housekeeping and employment responsibilities, and as a consequence, the patients experience high depression rates while the suicide incidence is high, varying from 28.6% to 2.5% in these patients.
Over the past 15 years a variety of studies have proved that exercise training in patients with chronic diseases, improve their functional capacity and quality of life, and accordingly are capable of performing their daily living activities independently, while it can reduce depression and delay the progression of the disease's symptoms.
Nevertheless, MS patients for many years were advised not to participate in exercise training programs because there was a perception that exercise could worsen the disease symptoms due to increased body temperature.
Indeed 60-80% of the MS patients present adverse clinical symptoms when their body temperature is increased not only due to physical working but even when immersing in hot water or by exposure to infrared lamps or the sun.
Since MS has a severe economic impact as it affects mostly young adults in their most productive years and leads to loss of work capacity and exercise training has the potential to prevent or ameliorate this loss, the need to develop new treatment strategies that could overcome the thermoregulatory problem during exercise is crucial.
Therefore, it has been proposed that active precooling is considered an effective treatment for reducing the consequences of induced-heat stress due to exercise.
Therefore, this study will examine whether a session of pre-cooling could improve the functional ability of patients with MS.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Thessaly
-
Tríkala, Thessaly, Greece, 42100
- FAME Lab, Department of Exercise Science, University of Thessaly
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Postmenopausal women (no menses for the last year at least);
- Osteoporosis patients (female): T-score<-2.5 at the femoral neck (or other anatomical site);
- Osteoporosis patients (male): T-score<-2.5 at the femoral neck (or other anatomical site)
- Osteopenia patients (female): T-score<-1.0 at the femoral neck (or other anatomical site);
- Osteopenia patients (male): T-score<-1.0 at the femoral neck (or other anatomical site)
- Patients taking drugs/ supplements for osteoporosis will be accepted in the study after going through a wash-up period
Exclusion Criteria:
- Women with irregular menses (i.e. with no established menopause)
- Patients taking medications for other diseases known to interfere with bone metabolism
- Patients with other chronic diseases (e.g. diabetes)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exercise with cooling
Assigned Interventions 10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study.
The exercise training session involved head cooling and neck wraps.
The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room.
Before and after the completion of the session each participant performed a variety of functional ability tests.
The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
|
The exercise training session involved head cooling and neck wraps.
Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room.
Before and after the completion of the condition each participant performed a variety of functional ability tests.
The evaluation of the core temperature and the assessment of the patient's quality of life also was performed
|
Active Comparator: Exercise without cooling
10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study.
The exercise session performed without cooling.
The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room.
Before and after the completion of the session each participant performed a variety of functional ability tests.
The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
|
The exercise session performed without cooling.
Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room.
Before and after the completion of the session each participant performed a variety of functional ability tests.
The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Core Temperature
Time Frame: Change from baseline to after 40 minutes of continous cycling.
|
The core temperature was measured using a telemetric capsule or (e-Celsius Performance, BodyCap, Caen, France).
Temperature at the skin surface was recorded every second at four sites using iBUTTON sensors (type DS1921 H, Maxim/Dallas Semiconductor Corp., USA) [Tsk; 0.3 (chest C arm) C 0.2 (thigh C leg)].
|
Change from baseline to after 40 minutes of continous cycling.
|
Functional ability test Handgrip
Time Frame: Change from baseline to after 40 minutes of continous cycling.
|
Handgrip dynamometer was used for the upper body muscle strength evaluation.
Both hands was tested.
|
Change from baseline to after 40 minutes of continous cycling.
|
Functional ability test 2-minute walk
Time Frame: Change from baseline to after 40 minutes of continous cycling.
|
The two-minute walk test was applied where all the patients had to cover as far a distance as possible over 2 minutes.
All the walking tests are related with the ability to perform independently the activities of daily living
|
Change from baseline to after 40 minutes of continous cycling.
|
Functional ability test 25-Foot Walk (T25-FW)
Time Frame: Change from baseline to after 40 minutes of continous cycling.
|
The 25-Foot Walk (T25-FW) was used to measure the walking speed.
It is a validated test that reflects the patient's mobility and leg function performance
|
Change from baseline to after 40 minutes of continous cycling.
|
Functional ability test five times sit-to-stand test (STS)
Time Frame: Change from baseline to after 40 minutes of continous cycling.
|
The five times sit-to-stand test (STS) was used as an indicator for lower limb strength, balance and mobility.
It has been reported that the STS times are associated with standing and leaning balance and mobility in older people.
Slow STS time have been also found to predict subsequent disability, falls and hip fractures
|
Change from baseline to after 40 minutes of continous cycling.
|
Functional ability test Berg Balance Scale (BBS)
Time Frame: Change from baseline to after 40 minutes of continous cycling.
|
The Berg Balance Scale (BBS) evaluates the performance in specific activities that require balance function.
The BBS test lasts approximately 20 minutes and involves common actions (e.g.
sit to stand, picking up an object, standing on one leg e.t.c.) necessary for activities of daily living.
The BBS is a 14-item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function.
|
Change from baseline to after 40 minutes of continous cycling.
|
Functional ability test level of fatigue severity (FSS)
Time Frame: Change from baseline to after 40 minutes of continous cycling.
|
The FSS is a 9-item self-report scale about fatigue of certain activities.
Its score includes a 7-point scale from 1 = strongly disagree to 7 = strongly agree.
The minimum possible score is nine and the highest is 63.
High score indicates severe fatigue.
FSS takes approximately eight minutes to complete.
|
Change from baseline to after 40 minutes of continous cycling.
|
Functional ability test Cognitive function
Time Frame: Change from baseline to after 40 minutes of continous cycling.
|
Cognitive function was assessed with the mini mental state examination (MMSE) questionnaire.
MMSE includes tests of orientation, attention, memory, language and visual-spatial skills.
The answers in the MMSE are scored as following: 0=incorrect, 1=correct, 6= item administered, participant does not answer and 9= unknown
|
Change from baseline to after 40 minutes of continous cycling.
|
Functional ability test level of fatigue impact
Time Frame: Change from baseline to after 40 minutes of continous cycling.
|
Level of fatigue was assessed by the Modified Fatigue Impact Scale (MFIS).
The MFIS contains the following sections: a) Physical Sub-scale (score 0-36), b) Cognitive Sub-scale (score 0-40) and Psychological Sub-scale (score 0-8).
The total MFIS score is 0-84; 0 represents the lower score and 84 represents the higher score.
|
Change from baseline to after 40 minutes of continous cycling.
|
Functional ability test level of fatigue inventory
Time Frame: Change from baseline to after 40 minutes of continous cycling.
|
Level of fatigue was assessed by the 20-item scale Multidimensional Fatigue Inventory (MFI) questionnaire.
The score of MFI is 1-7.
The more the fatigue, the higher the score.
|
Change from baseline to after 40 minutes of continous cycling.
|
Functional ability test level of physical fatigue
Time Frame: Change from baseline to after 40 minutes of continous cycling.
|
Level of fatigue was assessed by the Cognitive and Physical Fatigue in Multiple Sclerosis Scale (CPF-MS).
The CPF-MS score is 1-5.
The more the fatigue, the higher the score.
|
Change from baseline to after 40 minutes of continous cycling.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Antonia Kaltsatou, PhD, FAME Laboratory, Department of Exercise Science, University of Thessaly
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2019
Primary Completion (Actual)
June 25, 2019
Study Completion (Actual)
June 25, 2019
Study Registration Dates
First Submitted
October 8, 2019
First Submitted That Met QC Criteria
October 11, 2019
First Posted (Actual)
October 14, 2019
Study Record Updates
Last Update Posted (Actual)
October 14, 2019
Last Update Submitted That Met QC Criteria
October 11, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5. Multiple Sclerosis
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Exercise with cooling
-
University of OttawaRecruitingHyperthermia | Aging | Heat Stress | CoolingCanada
-
University of NebraskaCompletedExercise TrainingUnited States
-
Montefiore Medical CenterPaxmanRecruiting
-
Capital Medical UniversityNot yet recruitingAcute Ischemic Stroke
-
Karolinska InstitutetKarolinska University Hospital; University Hospital, Lille; Erasme University... and other collaboratorsCompletedOut-of-hospital Cardiac ArrestBelgium, Sweden
-
Fondation Ophtalmologique Adolphe de RothschildRecruiting
-
University Hospital, Basel, SwitzerlandActive, not recruiting
-
Karolinska InstitutetRecruitingVentricular Fibrillation | Hypothermia | Out-Of-Hospital Cardiac ArrestSweden, Spain, Germany, Belgium, Austria, Italy, Slovenia
-
University of OttawaCompletedAging | Physiological Stress | Heat StressCanada